Introduction
The February 2025 MFDS IND approval status shows that 42 investigational medicinal products were authorized for clinical trials in South Korea. Key trends include antibody‑drug conjugates (ADC), therapies for autoimmune diseases, mRNA combination vaccines and broader clinical‑trial trends. ADCs are therapeutic compounds that attach a cytotoxic or immunomodulatory payload to a monoclonal antibody via a linker, enabling precise delivery to target cells and minimizing off‑target toxicity.
Originally developed for oncology, ADCs are now being explored for autoimmune applications. At the same time, the mRNA platform has evolved to create combination vaccines that target both seasonal influenza and SARS‑CoV‑2. A recent review notes that Moderna’s mRNA‑1083 and Pfizer/BioNTech’s mRNA‑1020/1030 dual‑target vaccines both utilize mRNA technology and demonstrate strong immunogenicity and favorable safety profiles, with mRNA‑1083 eliciting higher immune responses. Such combination vaccines could simplify immunization strategies and strengthen preparedness for future outbreaks.
This report summarizes the February approvals, focusing on scientific background, technological implications and clinical prospects. It targets domestic and international professionals in the pharmaceutical and biotechnology sectors
Oncology: Waves of ADCs and Immuno‑oncology
Oncology accounts for the largest share of February approvals. Several ADCs and antibody therapies—such as MK‑2870, Ifinatamab Deruxtecan, M9140, HMBD‑001 and BI 770371—entered trials for ovarian, small‑cell lung, head‑and‑neck and esophageal cancers. ADCs comprise a monoclonal antibody, a linker and a cytotoxic payload; their mechanisms include direct internalization, extracellular payload release, immune‑mediated cytotoxicity and a bystander effect, allowing potent antitumor activity with reduced systemic toxicity.
The CAR‑T cell therapy YTB323 (rafkapta‑car‑T) was approved for lupus nephritis, reflecting the expanding role of cellular therapies beyond oncology. Other notable trials include checkpoint inhibitor combinations (atezolizumab + tarlatamab, BI 770371 + pembrolizumab) and HER2‑targeted agents (ZW25, trastuzumab formulations). Combined endocrine and cyclin‑dependent kinase inhibition (ribociclib + fulvestrant) also received approval, illustrating the move toward multimodal regimens tailored to tumor biology.
Autoimmune and Inflammatory Diseases
Approvals addressing autoimmune and inflammatory diseases include the HY209 gel for atopic dermatitis, CAR‑T therapy YTB323 for lupus nephritis, PN‑101 (mitochondria from umbilical cord mesenchymal stem cells) for polymyositis/dermatomyositis, dazodalibep for Sjögren’s syndrome and CT‑P13 (infliximab) subcutaneous formulations for Crohn’s disease and ulcerative colitis. Itepekimab targets chronic rhinosinusitis with nasal polyps, while re‑induction therapy with ustekinumab aims to restore response in Crohn’s disease. These trials represent attempts to modulate immune pathways using biologics, cell‑based approaches and cytokine inhibitors, thereby offering hope for patients with refractory inflammatory disorders.
Organ, Metabolic and Neurological Diseases
In organ and metabolic diseases, approvals include ALXN2030 for antibody‑mediated rejection after kidney transplantation, GDC‑8264 for preventing acute kidney injury after cardiac surgery and WAL0921 for glomerular disease and proteinuria. The aldosterone synthase inhibitor BI 690517 combined with empagliflozin targets chronic kidney disease and metabolic dysfunction. HODO‑2224 addresses hypertension with hypercholesterolemia, while Vutiglabridin tackles knee osteoarthritis and obesity. Further, LY3848575 for chronic neuropathic pain and PF‑07868489 for pulmonary arterial hypertension expand therapeutic options across cardiovascular, metabolic and neurological domains.
Infectious Diseases: mRNA Combination Vaccine
The most notable infectious‑disease approval was the mRNA‑1083 combination vaccine, which enters a Phase 3 trial evaluating immunogenicity, reactogenicity and safety in adults aged 50 and older. According to a review, Moderna’s mRNA‑1083 and Pfizer/BioNTech’s mRNA‑1020/1030 dual‑target vaccines demonstrate strong immunogenicity and favorable safety profiles; mRNA‑1083 elicited higher immune responses. This combination vaccine integrates mRNAs encoding antigens from SARS‑CoV‑2 and seasonal influenza strains, thereby offering broad protection with one injection. By condensing multiple vaccinations into a single dose, the vaccine could streamline annual immunization schedules and improve vaccine equity.
Trial Design and Other Trends
Early‑phase trials were prominent among February approvals. Acoramidis HCl aims to prevent transthyretin amyloidosis; DW5124, HODO‑2225 and MT102 evaluate pharmacokinetics and safety of novel compounds. Master protocols involving tarlatamab and zanidatamab combine targeted agents with chemotherapy or immune checkpoint inhibitors. Such designs foster efficiency, enabling simultaneous assessment of multiple regimens and faster identification of effective therapies. Roughly two‑thirds of approvals are internationally developed, yet domestic hospitals and biotech firms are increasingly participating, highlighting South Korea’s growing clinical‑trial capabilities.
Conclusions and Outlook
The February 2025 MFDS IND approvals reveal multifaceted progress: surging ADCs and immuno‑oncology, the advent of mRNA combination vaccines, and expansion of cell and gene therapies for autoimmune and inflammatory diseases. ADCs leverage mechanisms such as internalization, immune‑mediated cytotoxicity and bystander effects to attack tumors while sparing healthy tissue. Combination vaccines like mRNA‑1083 provide strong immunity against influenza and COVID‑19, simplifying immunization strategies and showing promising trial results. Moving forward, these innovations are expected to translate into regulatory approvals and broader treatment options. Personalized medicine—matching therapies to disease characteristics—will become increasingly important. South Korean companies can enhance competitiveness through global partnerships and innovative trial designs, while regulatory agencies should continue fostering a supportive environment for research and development.
Our company offers regulatory consulting, trial design, data management and approval strategy services for MFDS IND submissions. If your organization is planning a drug‑development or clinical‑trial project, please request a quote. Also, subscribe to our monthly newsletter to receive updates on MFDS IND approvals, regulatory changes and the latest clinical data. Click the banner on the right to subscribe easily.
